Haematologica, 2010 Background The presence of minimal residual disease detected by polymerase chain reaction techniques prior to allogeneic hematopoietic stem cell transplantation has proven to be an independent prognostic factor for poor outcome in children with acute ...
Izaskun Elorza +5 more
doaj +1 more source
Prognostic impact of KMT2A-AFF1-positivity in 926 BCR-ABL1-negative B-lineage acute lymphoblastic leukemia patients treated in GIMEMA clinical trials since 1996 [PDF]
, 2021 The impact of KMT2A-AFF1 rearrangement in pediatric-like, minimal residual disease (MRD)-based clinical trials and the effect of transplant in KMT2A-AFF1 ALL are still ...
Albano F. +19 more
core +1 more source
Minimal Residual Disease Detection in Acute Lymphoblastic Leukemia
International Journal of Molecular Sciences, 2020 Minimal residual disease (MRD) refers to a chemotherapy/radiotherapy-surviving leukemia cell population that gives rise to relapse of the disease. The detection of MRD is critical for predicting the outcome and for selecting the intensity of further ...
A. Kruse +10 more
semanticscholar +1 more source
Sensitive Detection of Minimal Residual Disease in Patients Treated for Early-Stage Breast Cancer
Clinical Cancer Research, 2020 Purpose: Existing cell-free DNA (cfDNA) methods lack the sensitivity needed for detecting minimal residual disease (MRD) following therapy. We developed a test for tracking hundreds of patient-specific mutations to detect MRD with a 1,000-fold lower ...
Heather A. Parsons +41 more
semanticscholar +1 more source
Blood Cancer Discovery, 2021 NGS-MRD >0 is highly predictive of relapse after tisagenlecleucel therapy for ALL. Serial monitoring of NGS-MRD and B-cell aplasia identifies high-risk patients with sufficient time for interventions to prevent relapse.
M. Pulsipher +21 more
semanticscholar +1 more source
Haematologica, 2016 Quantification of minimal residual disease may guide therapeutic strategies in mantle cell lymphoma. While multiparameter flow cytometry is used for diagnosis, the gold standard method for minimal residual disease analysis is real-time quantitative ...
Morgane Cheminant +19 more
doaj +1 more source
Liquid biopsies and minimal residual disease in myeloid malignancies
Frontiers in Oncology, 2023 Minimal residual disease (MRD) assessment through blood component sampling by liquid biopsies (LBs) is increasingly being investigated in myeloid malignancies.
Sabine Allam +9 more
doaj +1 more source
Clinical Applications and Future Directions of Minimal Residual Disease Testing in Multiple Myeloma
Frontiers in Oncology, 2020 In the last years, the life expectancy of multiple myeloma (MM) patients has substantially improved thanks to the availability of many new drugs. Our ability to induce deep responses has improved as well, and the treatment goal in patients tolerating ...
S. Oliva +3 more
semanticscholar +1 more source
Dynamics of Minimal Residual Disease in Neuroblastoma Patients
Frontiers in Oncology, 2019 Neuroblastoma is a common extracranial solid tumor of neural crest (NC) origin that accounts for up to 15% of all pediatric cancer deaths. The disease arises from a transient population of NC cells that undergo an epithelial-mesenchymal transition (EMT ...
Suguru Uemura +13 more
doaj +1 more source
Comparative analysis of Ig and TCR gene rearrangements at diagnosis and at elapse of childhood precursor-B–ALL provides improved strategies for selection of stable PCR targets for monitoring of minimal residual disease [PDF]
, 2002 Immunoglobulin (Ig) and T-cell receptor (TCR) gene rearrangements are excellent patient-specific polymerase chain reaction (PCR) targets for detection of minimal residual disease (MRD) in acute lymphoblastic leukemia (ALL), but they might be unstable ...
Brinkhof, B. (Bas) +5 more
core +2 more sources